<DOC>
	<DOCNO>NCT01714947</DOCNO>
	<brief_summary>This 2-part , open-label study 4 6 evaluable patient advance solid tumor lymphomas . This study intend provide quantitative characterization mass balance , rout metabolism , excretion pathway alisertib .</brief_summary>
	<brief_title>Mass Balance , Pharmacokinetics Metabolism Study Alisertib</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : 18 year old Histologically cytologically confirm metastatic and/or advance solid tumor lymphomas standard curative lifeprolonging treatment exist , longer effective tolerable Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Expected survival longer 3 month enrollment study Radiographically clinically evaluable tumor Suitable venous access conduct blood sampling Recovered reversible effect prior antineoplastic treatment ( exception alopecia Grade 1 neuropathy ) Female patient postmenopausal least 1 year OR surgically sterile OR childbearing potential , agree practice 2 effective method contraception time Male patient agree practice effective barrier contraception entire study 4 month last dose study drug OR agree abstain heterosexual intercourse Patients meet follow exclusion criterion enrol study : Female patient lactate positive serum pregnancy test Treatment investigational product systemic antineoplastic treatment within 21 day first dose alisertib . Medical condition require daily , chronic , regular use proton pump inhibitor ( PPIs ) within 7 day precede first dose alisertib , H2receptor antagonists within 24 hour precede first dose alisertib . Patient require systemic anticoagulation ( exclude lowdose aspirin , lowdose anticoagulation maintain patency venous access device ) . Low molecular weight heparin , administer preventive treatment , allow patient tolerate treatment stable dose schedule without bleed complication 1 month Major surgery within 14 day precede first dose alisertib Infection require systemic intravenous ( IV ) antibiotic therapy within 14 day precede first dose study drug , severe infection Lifethreatening uncontrolled medical illness unrelated cancer Ongoing nausea vomit Grade 2 bad intensity Diarrhea Grade 2 bad intensity use antimotility agent control diarrhea intensity Grade 1 low level . Known GI disease GI procedure could interfere oral absorption , excretion , tolerance alisertib History urinary and/or fecal incontinence History uncontrolled sleep apnea syndrome condition could result excessive daytime sleepiness severe chronic obstructive pulmonary disease Inability swallow tablet , inability unwillingness avoid take anything mouth except water prescribe medication 2 hour 1 hour first dose alisertib Inadequate bone marrow organ function specify study protocol Any cardiovascular condition specify study protocol Known suspect human immunodeficiency virus ( HIV ) positive hepatitis B surface antigenpositive status , know suspect active hepatitis C infection Inability comply study visit procedure include required inpatient confinement ( approximately 1117 day ) Please note additional exclusion criterion . The study center determine meet criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>